Xeris Pharmaceuticals (NASDAQ:XERS) posted its quarterly earnings results on Thursday. The company reported ($1.22) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.23) by $0.01, Fidelity Earnings reports. Xeris Pharmaceuticals had a negative net margin of 4,876.50% and a negative return on equity of 107.65%. The firm had revenue of $0.32 million during the quarter, compared to the consensus estimate of $0.20 million.
Shares of NASDAQ:XERS opened at $8.02 on Friday. The company has a market capitalization of $236.68 million, a price-to-earnings ratio of -1.61 and a beta of -0.49. Xeris Pharmaceuticals has a 52 week low of $6.85 and a 52 week high of $25.49. The company has a quick ratio of 6.00, a current ratio of 6.00 and a debt-to-equity ratio of 0.39. The firm has a 50 day moving average of $8.71 and a 200 day moving average of $10.49.
Several analysts have recently weighed in on XERS shares. Mizuho reaffirmed a “buy” rating and set a $22.00 price target on shares of Xeris Pharmaceuticals in a research note on Friday. ValuEngine downgraded shares of Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, September 30th. Finally, Royal Bank of Canada set a $18.00 price objective on shares of Xeris Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 7th.
About Xeris Pharmaceuticals
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
See Also: What is a front-end load?
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.